이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Rhythm Biosciences 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

David Atkins

최고 경영자

AU$409.2k

총 보상

CEO 급여 비율	12.1%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

CEO 보상 분석

David Atkins 의 보수는 Rhythm Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$409k	AU$49k	-AU$7m

보상 대 시장: David 의 총 보상 ($USD 275.68K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 309.27K ).

보상과 수익: CEO 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

David Atkins (59 yo)

less than a year

테뉴어

AU$409,243

보상

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024. He was Director of Cynata Therapeutics Limited from July 01, 2022 until November 2023. He...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Atkins	Chief Executive Officer	less than a year	AU$409.24k	데이터 없음
Guy Carisbrooke	Financial Controller	less than a year	AU$178.96k	데이터 없음
Andrea Steele	General Counsel & Joint Company Secretary	2.6yrs	데이터 없음	데이터 없음
James Barrie	Joint Company Secretary	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

경험이 풍부한 관리: RHY 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Otto Buttula	Non-Executive Chairman	4.9yrs	AU$369.11k	14.64% A$ 2.5m
Louis Panaccio	Non-Executive Director	7.1yrs	AU$66.86k	0.43% A$ 75.5k
Susan MacLeman	Independent Deputy Chair	1.7yrs	AU$87.74k	데이터 없음
Trevor Lockett	Non-Executive Director	7.3yrs	AU$227.26k	0.68% A$ 117.5k

6.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: RHY 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

Rhythm Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

Executive Chairman recently bought AU$248k worth of stock

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Recent updates

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령